MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 10 Million JPY | 19.86% |
| 2022 | 8.34 Million JPY | -29.25% |
| 2021 | 11.79 Million JPY | -40.79% |
| 2020 | 19.91 Million JPY | 5.46% |
| 2019 | 18.88 Million JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 10.04 Million JPY | -0.36% |
| 2024 Q2 | 12.25 Million JPY | 22.0% |
| 2023 Q3 | 9.23 Million JPY | 9.53% |
| 2023 Q4 | 10.07 Million JPY | 9.2% |
| 2023 Q1 | 7.06 Million JPY | -15.38% |
| 2023 FY | 10.07 Million JPY | 20.81% |
| 2023 Q2 | 8.42 Million JPY | 19.36% |
| 2022 Q3 | 16.09 Million JPY | 0.0% |
| 2022 FY | 8.34 Million JPY | -29.25% |
| 2022 Q4 | 8.34 Million JPY | -48.15% |
| 2021 FY | 11.79 Million JPY | -40.79% |
| 2020 FY | 19.91 Million JPY | 5.46% |
| 2019 FY | 18.88 Million JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.71 Billion JPY | 99.851% |
| Takeda Pharmaceutical Company Limited | 1209.86 Billion JPY | 99.999% |
| Sumitomo Pharma Co., Ltd. | 115.35 Billion JPY | 99.991% |
| Shionogi & Co., Ltd. | 64.91 Billion JPY | 99.985% |
| Wakamoto Pharmaceutical Co.,Ltd. | 2 Billion JPY | 99.502% |
| Nippon Shinyaku Co., Ltd. | 39.11 Billion JPY | 99.974% |
| Kaken Pharmaceutical Co., Ltd. | 17.16 Billion JPY | 99.942% |
| Eisai Co., Ltd. | 174.65 Billion JPY | 99.994% |
| Morishita Jintan Co., Ltd. | 3.18 Billion JPY | 99.686% |
| Hisamitsu Pharmaceutical Co., Inc. | 21.17 Billion JPY | 99.953% |
| Mochida Pharmaceutical Co., Ltd. | 30.27 Billion JPY | 99.967% |
| Fuso Pharmaceutical Industries,Ltd. | 14.2 Billion JPY | 99.93% |
| Nippon Chemiphar Co., Ltd. | 10.72 Billion JPY | 99.907% |
| Tsumura & Co. | 117.61 Billion JPY | 99.991% |
| Kissei Pharmaceutical Co., Ltd. | 26.29 Billion JPY | 99.962% |
| Torii Pharmaceutical Co., Ltd. | 10.74 Billion JPY | 99.907% |
| Towa Pharmaceutical Co., Ltd. | 101.07 Billion JPY | 99.99% |
| Fuji Pharma Co., Ltd. | 19.37 Billion JPY | 99.948% |
| Zeria Pharmaceutical Co., Ltd. | 14.48 Billion JPY | 99.931% |
| KYORIN Holdings, Inc. | 53.47 Billion JPY | 99.981% |
| Taiko Pharmaceutical Co.,Ltd. | 1.95 Billion JPY | 99.488% |
| Daito Pharmaceutical Co.,Ltd. | 20.89 Billion JPY | 99.952% |
| SymBio Pharmaceuticals Limited | 232.03 Million JPY | 95.69% |
| Mizuho Medy Co.,Ltd. | 1.59 Billion JPY | 99.374% |
| Solasia Pharma K.K. | 122 Million JPY | 91.803% |
| Modalis Therapeutics Corporation | 6.35 Million JPY | -57.406% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 20.4 Billion JPY | 99.951% |
| Sawai Group Holdings Co., Ltd. | 100 Billion JPY | 99.99% |
| Cyfuse Biomedical K.K. | 46.04 Million JPY | 78.282% |
| Toho Holdings Co., Ltd. | 87.28 Billion JPY | 99.989% |
| Koa Shoji Holdings Co.,Ltd. | 2.26 Billion JPY | 99.559% |